NCT00706862

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,100 (estimated)
• Sponsor: Agennix · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Talactoferrin	Oral, 1.5 grams twice per day
DRUG	Placebo	Oral, twice per day

Timeline

• Start date: 2009-02-01
• Primary completion: 2015-06-01
• Completion: 2016-03-01
• First posted: 2008-06-30
• Last updated: 2012-03-15

Locations

6 sites across 1 country: United States